schliessen

Filtern

 

Bibliotheken

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

INTRODUCTION: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward hi... Full description

Journal Title: Alzheimer's and Dementia (2019) (In press).
Main Author: Shi, L
Other Authors: Westwood, S , Baird, Al , Winchester, L , Dobricic, V , Kilpert, F , Hong, S , Franke, A , Hye, A , Ashton, Nj , Morgan, Ar , Bos, I , Vos, Sjb , Buckley, Nj , Kate, Mt , Scheltens, P , Vandenberghe, R , Gabel, S , Meersmans, K , Engelborghs, S , De Roeck, Ee , Sleegers, K , Frisoni, Gb , Blin, O , Richardson, Jc , Bordet, R , Molinuevo, Jl , Rami, L , Wallin, A , Kettunen, P , Tsolaki, M , Verhey, F , Lleó, A , Alcolea, D , Popp, J , Peyratout, G , Martinez - Lage, P , Tainta, M , Johannsen, P , Teunissen, Ce , Freund - Levi, Y , Frölich, L , Legido - Quigley, C , Barkhof, F , Blennow, K , Zetterberg, H , Baker, S , Morgan, Bp , Streffer, J , Visser, Pj , Bertram, L , Lovestone, S , Nevado - Holgado, Aj
Format: Electronic Article Electronic Article
Language: English
Subjects:
Tau
Quelle: University College London (UCL)
Created: 2019
Link: http://discovery.ucl.ac.uk/10081629/
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: ucl10081629
title: Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
format: Article
creator:
  • Shi, L
  • Westwood, S
  • Baird, Al
  • Winchester, L
  • Dobricic, V
  • Kilpert, F
  • Hong, S
  • Franke, A
  • Hye, A
  • Ashton, Nj
  • Morgan, Ar
  • Bos, I
  • Vos, Sjb
  • Buckley, Nj
  • Kate, Mt
  • Scheltens, P
  • Vandenberghe, R
  • Gabel, S
  • Meersmans, K
  • Engelborghs, S
  • De Roeck, Ee
  • Sleegers, K
  • Frisoni, Gb
  • Blin, O
  • Richardson, Jc
  • Bordet, R
  • Molinuevo, Jl
  • Rami, L
  • Wallin, A
  • Kettunen, P
  • Tsolaki, M
  • Verhey, F
  • Lleó, A
  • Alcolea, D
  • Popp, J
  • Peyratout, G
  • Martinez - Lage, P
  • Tainta, M
  • Johannsen, P
  • Teunissen, Ce
  • Freund - Levi, Y
  • Frölich, L
  • Legido - Quigley, C
  • Barkhof, F
  • Blennow, K
  • Zetterberg, H
  • Baker, S
  • Morgan, Bp
  • Streffer, J
  • Visser, Pj
  • Bertram, L
  • Lovestone, S
  • Nevado - Holgado, Aj
subjects:
  • Amyloid Β
  • Causal Relationship
  • Plasma Proteomics
  • Replication
  • Somascan Assay
  • Tau
ispartof: Alzheimer's and Dementia (2019) (In press).
description: INTRODUCTION: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. // METHODS: 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid. // RESULTS: A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. // DISCUSSION: The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition.
language: eng
source: University College London (UCL)
identifier:
fulltext: fulltext_linktorsrc
url: Link


@attributes
ID1364965835
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10081629
sourceiducl
recordidTN_ucl10081629
sourcesystemPC
display
typearticle
titleDiscovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
creatorShi, L ; Westwood, S ; Baird, Al ; Winchester, L ; Dobricic, V ; Kilpert, F ; Hong, S ; Franke, A ; Hye, A ; Ashton, Nj ; Morgan, Ar ; Bos, I ; Vos, Sjb ; Buckley, Nj ; Kate, Mt ; Scheltens, P ; Vandenberghe, R ; Gabel, S ; Meersmans, K ; Engelborghs, S ; De Roeck, Ee ; Sleegers, K ; Frisoni, Gb ; Blin, O ; Richardson, Jc ; Bordet, R ; Molinuevo, Jl ; Rami, L ; Wallin, A ; Kettunen, P ; Tsolaki, M ; Verhey, F ; Lleó, A ; Alcolea, D ; Popp, J ; Peyratout, G ; Martinez - Lage, P ; Tainta, M ; Johannsen, P ; Teunissen, Ce ; Freund - Levi, Y ; Frölich, L ; Legido - Quigley, C ; Barkhof, F ; Blennow, K ; Zetterberg, H ; Baker, S ; Morgan, Bp ; Streffer, J ; Visser, Pj ; Bertram, L ; Lovestone, S ; Nevado - Holgado, Aj
creationdate2019
ispartofAlzheimer's and Dementia (2019) (In press).
subjectAmyloid Β ; Causal Relationship ; Plasma Proteomics ; Replication ; Somascan Assay ; Tau
descriptionINTRODUCTION: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. // METHODS: 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid. // RESULTS: A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. // DISCUSSION: The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition.
languageeng
sourceUniversity College London (UCL)
oafree_for_read
links
openurl$$Topenurl_article
backlink$$Uhttp://discovery.ucl.ac.uk/10081629/$$EView_this_record_in_University_College_London_(UCL)
linktorsrc$$Uhttp://discovery.ucl.ac.uk/10081629/1/1-s2.0-S1552526019351180-main.pdf$$EView_full_text_in_University_College_London_(UCL)
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Shi, L
1Westwood, S
2Baird, Al
3Winchester, L
4Dobricic, V
5Kilpert, F
6Hong, S
7Franke, A
8Hye, A
9Ashton, Nj
10Morgan, Ar
11Bos, I
12Vos, Sjb
13Buckley, Nj
14Kate, Mt
15Scheltens, P
16Vandenberghe, R
17Gabel, S
18Meersmans, K
19Engelborghs, S
20De Roeck, Ee
21Sleegers, K
22Frisoni, Gb
23Blin, O
24Richardson, Jc
25Bordet, R
26Molinuevo, Jl
27Rami, L
28Wallin, A
29Kettunen, P
30Tsolaki, M
31Verhey, F
32Lleó, A
33Alcolea, D
34Popp, J
35Peyratout, G
36Martinez - Lage, P
37Tainta, M
38Johannsen, P
39Teunissen, Ce
40Freund - Levi, Y
41Frölich, L
42Legido - Quigley, C
43Barkhof, F
44Blennow, K
45Zetterberg, H
46Baker, S
47Morgan, Bp
48Streffer, J
49Visser, Pj
50Bertram, L
51Lovestone, S
52Nevado - Holgado, Aj
titleDiscovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
descriptionINTRODUCTION: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. // METHODS: 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid. // RESULTS: A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. // DISCUSSION: The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition.
subject
0Amyloid Β
1Causal Relationship
2Plasma Proteomics
3Replication
4Somascan Assay
5Tau
general
0English
1UCL Discovery (University College London)
sourceiducl
recordiducl10081629
rsrctypearticle
creationdate2019
addtitleAlzheimer's and Dementia (2019) (In press)
searchscopeucl
scopeucl
sort
titleDiscovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
authorShi, L ; Westwood, S ; Baird, Al ; Winchester, L ; Dobricic, V ; Kilpert, F ; Hong, S ; Franke, A ; Hye, A ; Ashton, Nj ; Morgan, Ar ; Bos, I ; Vos, Sjb ; Buckley, Nj ; Kate, Mt ; Scheltens, P ; Vandenberghe, R ; Gabel, S ; Meersmans, K ; Engelborghs, S ; De Roeck, Ee ; Sleegers, K ; Frisoni, Gb ; Blin, O ; Richardson, Jc ; Bordet, R ; Molinuevo, Jl ; Rami, L ; Wallin, A ; Kettunen, P ; Tsolaki, M ; Verhey, F ; Lleó, A ; Alcolea, D ; Popp, J ; Peyratout, G ; Martinez - Lage, P ; Tainta, M ; Johannsen, P ; Teunissen, Ce ; Freund - Levi, Y ; Frölich, L ; Legido - Quigley, C ; Barkhof, F ; Blennow, K ; Zetterberg, H ; Baker, S ; Morgan, Bp ; Streffer, J ; Visser, Pj ; Bertram, L ; Lovestone, S ; Nevado - Holgado, Aj
creationdate20190000
facets
frbrgroupid6131124193420655313
frbrtype6
newrecords20190918
languageeng
creationdate2019
topic
0Amyloid Β
1Causal Relationship
2Plasma Proteomics
3Replication
4Somascan Assay
5Tau
collectionUCL Discovery (University College London)
prefilterarticles
rsrctypearticles
creatorcontrib
0Shi, L
1Westwood, S
2Baird, Al
3Winchester, L
4Dobricic, V
5Kilpert, F
6Hong, S
7Franke, A
8Hye, A
9Ashton, Nj
10Morgan, Ar
11Bos, I
12Vos, Sjb
13Buckley, Nj
14Kate, Mt
15Scheltens, P
16Vandenberghe, R
17Gabel, S
18Meersmans, K
19Engelborghs, S
20De Roeck, Ee
21Sleegers, K
22Frisoni, Gb
23Blin, O
24Richardson, Jc
25Bordet, R
26Molinuevo, Jl
27Rami, L
28Wallin, A
29Kettunen, P
30Tsolaki, M
31Verhey, F
32Lleó, A
33Alcolea, D
34Popp, J
35Peyratout, G
36Martinez - Lage, P
37Tainta, M
38Johannsen, P
39Teunissen, Ce
40Freund - Levi, Y
41Frölich, L
42Legido - Quigley, C
43Barkhof, F
44Blennow, K
45Zetterberg, H
46Baker, S
47Morgan, Bp
48Streffer, J
49Visser, Pj
50Bertram, L
51Lovestone, S
52Nevado - Holgado, Aj
jtitleAlzheimer's and Dementia (2019) (In press)
delivery
delcategoryRemote Search Resource
fulltextfulltext_linktorsrc
addata
aulast
0Shi
1Westwood
2Baird
3Winchester
4Dobricic
5Kilpert
6Hong
7Franke
8Hye
9Ashton
10Morgan
11Bos
12Vos
13Buckley
14Kate
15Scheltens
16Vandenberghe
17Gabel
18Meersmans
19Engelborghs
20De Roeck
21Sleegers
22Frisoni
23Blin
24Richardson
25Bordet
26Molinuevo
27Rami
28Wallin
29Kettunen
30Tsolaki
31Verhey
32Lleó
33Alcolea
34Popp
35Peyratout
36Martinez-Lage
37Tainta
38Johannsen
39Teunissen
40Freund-Levi
41Frölich
42Legido-Quigley
43Barkhof
44Blennow
45Zetterberg
46Baker
47Streffer
48Visser
49Bertram
50Lovestone
51Nevado-Holgado
aufirst
0L
1S
2AL
3V
4F
5A
6NJ
7AR
8I
9SJB
10MT
11P
12R
13K
14EE
15GB
16O
17JC
18JL
19M
20D
21J
22G
23CE
24Y
25C
26H
27BP
28PJ
29AJ
au
0Shi, L
1Westwood, S
2Baird, Al
3Winchester, L
4Dobricic, V
5Kilpert, F
6Hong, S
7Franke, A
8Hye, A
9Ashton, Nj
10Morgan, Ar
11Bos, I
12Vos, Sjb
13Buckley, Nj
14Kate, Mt
15Scheltens, P
16Vandenberghe, R
17Gabel, S
18Meersmans, K
19Engelborghs, S
20De Roeck, Ee
21Sleegers, K
22Frisoni, Gb
23Blin, O
24Richardson, Jc
25Bordet, R
26Molinuevo, Jl
27Rami, L
28Wallin, A
29Kettunen, P
30Tsolaki, M
31Verhey, F
32Lleó, A
33Alcolea, D
34Popp, J
35Peyratout, G
36Martinez - Lage, P
37Tainta, M
38Johannsen, P
39Teunissen, Ce
40Freund - Levi, Y
41Frölich, L
42Legido - Quigley, C
43Barkhof, F
44Blennow, K
45Zetterberg, H
46Baker, S
47Morgan, Bp
48Streffer, J
49Visser, Pj
50Bertram, L
51Lovestone, S
52Nevado - Holgado, Aj
atitleDiscovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
jtitleAlzheimer's and Dementia (2019) (In press)
date2019
risdate2019
genrearticle
ristypeJOUR
abstractINTRODUCTION: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. // METHODS: 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid. // RESULTS: A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. // DISCUSSION: The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition.
urlhttp://discovery.ucl.ac.uk/10081629/1/1-s2.0-S1552526019351180-main.pdf
formatarticle
oafree_for_read